Joint effects of N-terminal pro-B-type-natriuretic peptide and C-reactive protein vs angiographic severity in predicting major adverse cardiovascular events and clinical restenosis after coronary angioplasty in patients with stable coronary artery disease

Circulation Journal

Volumn 72, Issue 8, 2008, Pages 1316-1323

  Dai, Dao Fu ^a   Hwang, Juey Jen ^a   Lin, Jiunn Lee ^a   Lin, Jou Wei ^a   Hsu, Chih Neng ^a   Lin, Chih Min ^a   Chiang, Fu Tien ^a   Lai, Ling Ping ^a   Hsu, Kwan Lih ^a   Tseng, Chuen Den ^a   Tseng, Yung Zu ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Brain; C reactive protein (CRP); Coronary artery disease; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE SEVERITY; FEMALE; GENSINI SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; RESTENOSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 48749130793     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.1316     Document Type: Article

References (34)

1. Hall C. NT-ProBNP: The mechanism behind the marker. J Card Fail 2005; 11(Suppl): S81-S83.
2. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004; 44: 1988-1995.
3. Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352: 666-675.
4. Goetze JP, Mogelvang R, Maage L, Scharling H, Schnohr P, Sogaard P, et al. Plasma pro-B-type natriuretic peptide in the general population: Screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 2006; 27: 3004-3010.
5. de Lemos JA, McGuire DK, DraznerMH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-322.
6. Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, et al. Incremental prognostic value of C-reactive protein and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome. Circ J 2006; 70: 1379-1384.
7. Sakai H, Tsutamoto T, Ishikawa C, Tanaka T, Fujii M, Yamamoto T, et al. Direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP secretion and extent of coronary artery stenosis in patients with stable coronary artery disease. Circ J 2007; 71: 499-505.
8. Ogawa A, Seino Y, Yamashita T, Ogata K, Takano T. Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. Circ J 2006; 70: 1372-1378.
9. Paul A, Yeh ET, Chan L. A proatherogenic role for C-reactive protein in vivo. Curr Opin Lipidol 2005; 16: 512-517.
10. Yaron G, Brill A, Dashevsky O, Yosef Levi IM, Grad E, Danenberg HD, et al. C-reactive protein promotes platelet adhesion to endothelial cells: A potential pathway in atherothrombosis. Br J Haematol 2006; 134: 426-431.
11. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit?: C-reactive protein promotes atherothrombosis. Circulation 2006; 113: 2135-2150; discussion 2150.
12. Weber M, Dill T, Arnold R, Rau M, Eldnci O, Müller KD, et al. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 2004; 148: 612-620.
13. Dai DF, Lin JW, Kao JH, Hsu CN, Chiang FT, Lin JL, et al. The effects of metabolic syndrome versus infectious burden on inflammation, severity of coronary atherosclerosis, and major adverse cardiovascular events. J Clin Endocrinol Metab 2007; 92: 2532-2537.
14. Tataru MC, Heinrich J, Junker R, Schulte H, von Ekardstein A, Assman G, et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 2000; 21: 1000-1008.
15. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397.
16. Ringqvist L Fisher LD, Mock M, Davis KB, Wedel H, Chaitman BR, et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest 1983; 71: 1854-1866.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from semm creatinine: A new prediction equation: Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470.
18. De Long ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44: 837-845.
19. Schillinger M, Exner M, Amighi J, Mlekusch W, Sabeti S, Rumpold H, et al. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation 2003; 108: 2323-2328.
20. Ndrepepa G, Kastrati A, Braun S, Mehilli J, Niemöller K, Von Beckerath N, et al. N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease. Am J Med 2006; 119: e351-e358.
21. Schnabel R, Rupprecht HJ, Lackner KJ, Lubos E, Bickel C, Meyer J, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: Results from the AtheroGene study. Eur Heart J 2005; 26: 241-249.
22. Sinning JM, Bickel C, Messow CM, Schnabel R, Lubos E, Rupprecht HJ, et al. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: The AtheroGene study. Eur Heart J 2006; 27: 2962-2968.
23. Pascual-Figal DA, Antolinos MJ, Bayes-Genis A, Casas T, Nicolas F, Vaidés M. B-type natriuretic peptide release in the coronary effluent after acute transient ischemia in humans. Heart 2007; 93: 1077-1080.
24. Williams TN, Zhang CX, Game BA, He L, Huang Y. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc [gamma]RII and extracellular signal-regulated kinase pathway: An implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vase Biol 2004; 24: 61-66.
25. Bisoendial RJ, Kastelein JJ, Levels IH, Zwaginger JJ, van den Bogaard B, Reitsma PH, et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96: 714-716.
26. Walter DH, Fichtlscherer S, SeUwig M, Auch-Schwelk W, Schlächinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37: 839-846.
27. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazotti V, Rebuzzi AG, et al. Preprocedural semm levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34: 1512-1521.
28. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilanou HI, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The global evaluation of new events and restenosis after stent implantation study. J Am Coll Cardiol 2002; 40: 1375-1382.
29. Rittersma SZ, de Winter RJ, Koch KT, Schotborgh CE, Bax M, Heyde GS, et al. Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement. Clin Chem 2004; 50: 1589-1596.
30. Hong SN, Ahn Y, Hwang SH, Yoon NS, Lee SR, Moon JY, et al. Usefulness of semm N-terminal pro-brain natriuretic peptide to predict in-stent restenosis in patients with preserved left ventricular function and normal troponin I levels. Am J Cardiol 2007; 99: 1051-1054.
31. Stmthers A, Lang C. The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. Eur Heart J 2007; 28: 1678-1682.
32. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, et al. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 2005; 150: 344-350.
33. Gach O, Legrand V, Biessaux Y, Chapelle JP, Vanbelle S, Pierard LA. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol 2007; 99: 31-35.
34. Kwan G, Isakson SR, Beede J, Clopton P, Maisel AS, Fitzgerald RL. Short-term serial sampling of natriuretic peptides in patients presenting with chest pain. J Am Coll Cardiol 2007; 49: 1186-1192.